@article{46166f8e86094a22a8921e9d785924be,
title = "Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents",
abstract = "ONJ is an important toxicity in cancer patients receiving bisphosphonate therapy. Here we report a higher than usual incidence of ONJ, 11 of 60 (18.3%, 95% Confidence Interval, CI: 9%-28%) patients enrolled in a phase II clinical trial combining bevacizumab, docetaxel, thalidomide, and prednisone (ATTP) in chemotherapy-naive men with metastatic castration resistant prostate cancer (mCRPC). The use of bisphosphonates was allowed at study entry. Our study suggests that anti-angiogenic and chemotherapy agents can predispose to the development of ONJ in men with mCRPC on zoledronic acid. Imaging modalities, such as bone scans, may be useful in following the clinical course of patients who develop ONJ.",
keywords = "Anti-angiogenesis, Bisphosphonates, Chemotherapy, Osteonecrosis of the jaw, Prostate pancer",
author = "Aragon-Ching, {Jeanny B.} and Ning, {Yang Min} and Chen, {Clara C.} and Lea Latham and Guadagnini, {Jean Pierre} and Gulley, {James L.} and Arlen, {Philip M.} and Wright, {John J.} and Howard Parnes and Figg, {William D.} and Dahut, {William L.}",
note = "Funding Information: This project has been supported by the Intramural Research Program of the National Cancer Institute, Center for Cancer Research, National Institutes of Health. The content of this publication does not reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.",
year = "2009",
month = feb,
doi = "10.1080/07357900802208608",
language = "English",
volume = "27",
pages = "221--226",
journal = "Cancer Investigation",
issn = "0735-7907",
publisher = "Taylor & Francis Group LLC Philadelphia",
number = "2",
}